Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease

American Journal of Hypertension

Volumn 26, Issue 9, 2013, Pages 1155-1161

  Chan, Doris T ^a,b   Watts, Gerald F ^a   Irish, Ashley B ^c   Ooi, Esther M M ^a   Dogra, Gursharan K ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

blood pressure; chronic kidney disease; hypertension; insulin resistance; metabolic syndrome; vascular function.

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DYSGLYCEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PULSE WAVE; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME; VASCULAR FUNCTION.;

ADULT; AGED; AUSTRALIA; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, BIOLOGICAL; PULSE WAVE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR DISEASES; VASCULAR STIFFNESS; WAIST CIRCUMFERENCE;

EID: 84882344914     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt077     Document Type: Article

References (30)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
2. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16:1091-1098.
3. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13:1894-1900.
4. Dogra G, Irish A, Chan D, Watts G. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 2006; 48:926-934.
5. Fathi R, Haluska B, Isbel N, Short L, Marwick TH. The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 2004; 43:616-623.
6. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99:2434-2439.
7. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T, Nishizawa Y. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12:2117-2124.
8. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38:434-438.
9. Johnson DW, Armstrong K, Campbell SB, Mudge DW, Hawley CM, Coombes JS, Prins JB, Isbel NM. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton, Vic) 2007; 12:391-398.
10. Young DO, Lund RJ, Haynatzki G, Dunlay RW. Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int 2007; 11:86-95.
11. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.
12. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Cakar M, Altun B, Yenicesu M, Carrero JJ. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 2011; 26:3537-3543.
13. Chan DT, Watts GF, Irish AB, Dogra GK. Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrol Dian Transplant 2011; 26:3543-3549.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
15. Tatar E, Demirci MS, Kircelli F, Gungor O, Turan MN, Sevinc Ok E, Asci G, Ozkahya M, Ok E. Association of insulin resistance with arterial stiffness in nondiabetic peritoneal dialysis patients. Int Urol Nephrol 2012; 44:255-262.
16. Dogra G, Kanganas C, Chan DC, Irish A, Watts G. The Metabolic Syndrome as a predictor of Impaired Vascular Function in Chronic Kidney Disease. Nephrology (Carlton) 2005; 10:A408.
17. Lee P, O'Neal D, Murphy B, Best J. The role of abdominal adiposity and insulin resistance in dyslipidemia of chronic renal failure. Am J Kidney Dis 1997; 29:54-65.
18. Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PH, Chan DC, Watts GF. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res 2009; 50:2524-2531.
19. Irish AB. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism 1997; 46:36-40.
20. Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, Lash JP, Chen J, Steigerwalt SP, Flack J, Go AS, Rafey M, Rahman M, Sheridan A, Gadegbeku CA, Robinson NA, Joffe M. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 2010; 23:282-289.
21. Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 2005; 45:592-596.
22. Shinohara K, Shoji T, Tsujimoto Y, Kimoto E, Tahara H, Koyama H, Emoto M, Ishimura E, Miki T, Tabata T, Nishizawa Y. Arterial stiffness in predialysis patients with uremia. Kidney Int 2004; 65:936-943.
23. Banerjee D, Recio-Mayoral A, Chitalia N, Kaski JC. Insulin resistance, inflammation, and vascular disease in nondiabetic predialysis chronic kidney disease patients. Clin Cardiol 2011; 34:360-365.
24. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003; 108:1527-1532.
25. Tomiyama H, Koji Y, Yambe M, Motobe K, Shiina K, Gulnisa Z, Yamamoto Y, Yamashina A. Elevated C-reactive protein augments increased arterial stiffness in subjects with the metabolic syndrome. Hypertension 2005; 45:997-1003.
26. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51:527-539.
27. Zhe XW, Zeng J, Tian XK, Chen W, Gu Y, Cheng LT, Chen HM, Axelsson J, Lindholm B, Wang T. Pulse wave velocity is associated with metabolic syndrome components in CAPD patients. Am J Nephrol 2008; 28:641-646.
28. Liao C-T, Kao T-W, Chou Y-H, Wu M-S, Chen Y-M, Chuang H-F, Hung K-Y, Chu T-S, Wu K-D, Tsai T-J. Associations of metabolic syndrome and its components with cardiovascular outcomes among non-diabetic patients undergoing maintenance peritoneal dialysis. Nephrol Dial Transplant 2011; 26:4047-4054.
29. Wu C-C, Liou H-H, Su P-F, Chang M-Y, Wang H-H, Chen M-J, Hung S-Y. Abdominal obesity is the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients. Nephrol Dial Transplant 2011; 26:3689-3695.
30. Simons LA, Simons J, Friedlander Y, McCallum J. Usefulness of fasting plasma glucose to predict mortality or coronary heart disease in persons 60 years of age without diabetes mellitus or in those with undiagnosed diabetes mellitus (from The Dubbo Study). Am J Cardiol 2008; 102:831-834.